Colin Bristow
Stock Analyst at UBS
(1.05)
# 3,392
Out of 4,810 analysts
93
Total ratings
29.09%
Success rate
-15.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.10 | +263.64% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $4.00 | +75.00% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $22.12 | +26.58% | 13 | Feb 5, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $4 → $2.2 | $0.50 | +338.86% | 5 | Jan 27, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $79.17 | +51.57% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $45.08 | +57.50% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $106.50 | -9.86% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $495.83 | +18.19% | 13 | Nov 5, 2024 | |
| AMGN Amgen | Maintains: Neutral | $335 → $326 | $293.92 | +10.91% | 7 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Neutral | $234 → $202 | $119.26 | +69.38% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $41 | $15.43 | +165.72% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.92 | +733.33% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $571.06 | +92.45% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $5.91 | +813.71% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $54.63 | +205.69% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $754.35 | -44.32% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $6.99 | -71.39% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.74 | +2,332.43% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $179.10 | -18.48% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $51.34 | +46.08% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.23 | +2,013.82% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.17 | +74.08% | 1 | Aug 23, 2021 |
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.10
Upside: +263.64%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $4.00
Upside: +75.00%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $22.12
Upside: +26.58%
ALX Oncology Holdings
Jan 27, 2025
Maintains: Buy
Price Target: $4 → $2.2
Current: $0.50
Upside: +338.86%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $79.17
Upside: +51.57%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $45.08
Upside: +57.50%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $106.50
Upside: -9.86%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $495.83
Upside: +18.19%
Amgen
Oct 31, 2024
Maintains: Neutral
Price Target: $335 → $326
Current: $293.92
Upside: +10.91%
Biogen
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $119.26
Upside: +69.38%
Aug 13, 2024
Maintains: Buy
Price Target: $42 → $41
Current: $15.43
Upside: +165.72%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.92
Upside: +733.33%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $571.06
Upside: +92.45%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $5.91
Upside: +813.71%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $54.63
Upside: +205.69%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $754.35
Upside: -44.32%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $6.99
Upside: -71.39%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $0.74
Upside: +2,332.43%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $179.10
Upside: -18.48%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $51.34
Upside: +46.08%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.23
Upside: +2,013.82%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.17
Upside: +74.08%